NCT01225913View on ClinicalTrials.gov

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Asthma
Interventions
DRUG

fluticasone/salmeterol in all asthmatics

budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days

DRUG

budesonide/formoterol or fluticasone/salmeterol in all asthmatics

budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid

Trial Locations (1)

90712

RECRUITING

Arthur F Gelb Medical Corporation, Lakewood

All Listed Sponsors
lead

Gelb, Arthur F., M.D.

INDIV